Hide and seek... Can we eradicate HIV by treatment intensification?

Journal of Infectious Diseases

Volumn 203, Issue 7, 2011, Pages 894-897

  Zur Wiesch, Julian Schulze ^a,b   Van Lunzen, Jan ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COMPLEMENTARY DNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; DNA REPAIR; DRUG ACTIVITY; DRUG POTENCY; DRUG TREATMENT FAILURE; EDITORIAL; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONG TERMINAL REPEAT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VIREMIA; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 79953006500     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq150     Document Type: Editorial

References (29)

1. Ostrowski SR. Immune, activation in chronic HIV infection. Dan Med Bull; 57:B4122.
2. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-84. (Pubitemid 351723493)
3. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71. (Pubitemid 44924494)
4. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7. (Pubitemid 29220209)
5. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300. (Pubitemid 27495742)
6. Hatano H, Tzong- Hae Lee P, Peter WH, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011. doi:10.1093/infdis/jiq138.
7. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16:460-5.
8. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50:912-9.
9. Gandhi RT, Zheng L, Bosch RJ. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7.
10. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24(16):2451-60.
11. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-21. (Pubitemid 350287458)
12. Schacker T. New tools to track HIV. Nat Med 16:373-4.
13. Hauber I, Harrer T, Low P, Schmitt M, Schwingel E, Hauber J. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads. AIDS 2000; 14:2619-21.
14. Delaugerre C, Charreau I, Braun J, et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS 24:2391-5.
15. Grant PM, Palmer S, Bendavid E, et al. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol 2009; 46:305-8.
16. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24:2803-8.
17. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-8.
18. Rozenbaum W, Katlama C, Massip P, et al. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Antivir Ther 2001; 6:135-42. (Pubitemid 32652098)
19. Sayana S, Hamwi G, DenOuden P, Easley A, Khanlou H. The use of darunavir/ritonavir as intensification in low viremic HIV-infected patients treated with boosted protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic Ill) 2009; 8:21-2.
20. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18:665-708. (Pubitemid 30365394)
21. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
22. Hutter G, Allers K, Schneider T. The additional use of viral entry inhibitors during autologous hematopoietic stem cell transplantation in patients with non-Hodgkin s lymphoma and HIV-1 infection. Biol Blood Marrow Transplant 2009. doi:10.1016/j. bbmt.2009.10.030.
23. Hutter G, Schneider T, Thiel E. Transplantation of selected or transgenic blood stem cells - a future treatment for HIV/ AIDS? J Int AIDS Soc 2009; 12:10.
24. Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007; 316: 1912-5.
25. McElrath MJ. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J Infect Dis 202 (Suppl 2):S323-6.
26. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-84.
27. Josefsson L, Dahl V, Palmer S. Can HIV infection be eradicated through use of potent antiviral agents? Curr Opin Infect Dis 23:628-32.
28. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of longterm drug-free remissions for HIV-infected individuals. Science 329:174-80.
29. Murray SM, Down CM, Boulware DR, et al. Reduction of immune activation during chronic HIV infection with Chloroquine therapy. J Virol 2010; 84:12082-6.